Costs force Quidel to settle patent case:
This article was originally published in Clinica
Quidel has given up defending the patent action brought by Becton Dickinson, citing costs and uncertainty of litigation and the diversion of management time. The US company has agreed to pay Becton an annual $1.9 million in licence fees and royalties. The company develops tests for strep, chlamydia and h pylori and the patents in contention covered a large part of Quidel's business.